Journal: International Journal of Biological Sciences
Article Title: Apigenin Suppresses Bladder Cancer via the SIRT6-NCOA2-PPARα Axis
doi: 10.7150/ijbs.128177
Figure Lengend Snippet: Apigenin enhances SIRT6-NCOA2 interaction, promotes NCOA2 deacetylation, and is associated with PPARα signaling activation. (A) Quantification summary of acetylated proteomics data. Paired bar graphs display identified and quantified acetylation sites, peptides, and proteins. (B) The number of modification sites in a protein. (C) Clustering heatmap of differential acetylation sites. Each row represents a lysine acetylation modification site (labeled as "protein name_K position"), and each column represents a sample (including the control group and various treatment doses). The right panel presents the p value for the comparison between the highest dose group (100) and the control group (0). The color reflects the relative acetylation levels of each site across the samples (Z-score) red indicates higher acetylation, while blue indicates lower acetylation. (D) Protein-Protein Interaction (PPI) Network of 19 genes. (E) WikiPathways enrichment analysis of differentially expressed proteins. Each circle represents an enriched pathway, with circle size proportional to the number of differentially expressed proteins in that pathway. The color corresponds to the statistical significance of the enrichment (warmer colors indicate more significant FDR values). (F) Schematic representation of post-translational modification sites in the NCOA2 protein. (G) Proteomic acetylation analysis reveals that apigenin treatment reduces acetylation of NCOA2 at lysine residues K780 and K785 (n=3). (H) Heatmap of deacetylase family protein expression. The upper graph shows proteomic data, and the lower graph shows transcriptomic data. Rows represent classical HDAC enzymes (classified as Class I, IIa, IIb, and IV) and Sirtuin family proteins (SIRT1-7), and columns correspond to different treatment group samples (T24+0 control and 20, 40, 100 µM treatment groups). The color represents the relative abundance of gene expression as a Z-score (red indicates higher expression compared to the control average, blue indicates lower expression). (I-J) Apigenin (100 μM) enhances the interaction between SIRT6 and NCOA2, as demonstrated by co-immunoprecipitation. (K) Acetylation levels of NCOA2 in T24 cells following apigenin treatment were detected using a pan-acetyl lysine antibody. (L) Pan-acetyl lysine antibody was used to assess acetylation levels of wild-type NCOA2 and its K780R, K785R, K780Q, K785Q single and double mutants following apigenin stimulation. (M) Molecular docking simulation of apigenin with SIRT6, showing a binding score of -7.6 kcal/mol. (N) Dual-luciferase reporter assays were conducted to evaluate PPARα transcriptional activity in T24 cells stably expressing NCOA2 K780R/K785R, K780Q/K785Q, or wild-type NCOA2 under apigenin treatment (n=4). (O-P) Apigenin enhances the expression of key enzymes involved in fatty acid β-oxidation, including FASN, ACC, CPT1A, and ACOX1, through deacetylation of NCOA2 at K780 and K785 sites (n=3). Statistical comparisons were performed using one-way ANOVA followed by Tukey's post hoc test. Data are presented as mean ± SD. P values are indicated as follows: * p < 0.05 , ** p < 0.01, *** p < 0.001 , **** p < 0.0001; ns = not significant, compared to the control group.
Article Snippet: Lysates were incubated with Protein A+G magnetic beads (Beyotime, China, P2179M) pre-coupled with NCOA2 (CST, USA, 96687), FLAG (Proteintech, China, 66008-4-Ig), or SIRT6 (Abcam, UK, ab191385) antibodies.
Techniques: Activation Assay, Modification, Labeling, Control, Comparison, Histone Deacetylase Assay, Expressing, Gene Expression, Immunoprecipitation, Binding Assay, Luciferase, Activity Assay, Stable Transfection